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Abstract Cholecystokinin (CCK) receptors are overex-
pressed in numerous human cancers, like medullary thyroid
carcinomas, small cell lung cancers and stromal ovarian
cancers. The speciﬁc receptor-binding property of the
endogenous ligands for these receptors can be exploited by
labeling peptides with a radionuclide and using these as
carriers to guide the radioactivity to the tissues that express
the receptors. In this way, tumors can be visualized using
positron emission tomography and single photon emission
computed tomography imaging. A variety of radiolabeled
CCK/gastrin-related peptides has been synthesized and
characterized for imaging. All peptides have the C-terminal
CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-
Phe-NH2 in common or derivatives thereof. This review
focuses on the development and application of radiolabeled
CCK/gastrin peptides for radionuclide imaging and radio-
nuclide therapy of tumors expressing CCK receptors. We
discuss both preclinical studies as well as clinical studies
with CCK and gastrin peptides.
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Introduction on peptide receptor radionuclide imaging
and therapy
Regulatory peptide receptors, such as somatostatin recep-
tors, cholecystokinin (CCK) receptors, glucagon-like pep-
tide-1 (GLP-1) receptors and gastrin-releasing peptide
(GRP) receptors, are overexpressed in numerous human
cancers. Endogenous ligands for the regulatory receptors
are potent low molecular weight peptides that are mainly
synthesized in the central nervous system and the gastro-
intestinal tract (Be ´he ´ and Behr 2002; Behr and Be ´he ´ 2002).
Because of their low molecular weight, the regulatory
peptides can rapidly penetrate tissues, except for the brain,
because the peptides are too hydrophilic to pass through the
blood–brain barrier. Therefore, the central nervous system
and the gastrointestinal tract can use the same messenger
molecules without mutual interference. The speciﬁc
receptor-binding property of peptides can be exploited by
labeling the peptides with a radionuclide and using these as
carriers to guide the radioactivity to the tissues that express
their speciﬁc receptors.
Imaging modalities that are used in nuclear medicine are
positron emission tomography (PET) and single photon
emission computed tomography (SPECT). PET involves
the use of short-lived b
?-emitting radionuclides, like
18F
and
68Ga. Positrons annihilate with electrons, causing two c
photons of 511 keV to be emitted in opposite directions. A
PET scanner detects these emissions coincidentally and
provides high-resolution images. The SPECT imaging
technique detects c-photons directly from the radiotracer.
SPECT imaging is less expensive than PET since different
c-emitting radionuclides can be used, which are mostly
longer-lived and more easy to obtain than PET tracers.
One of the requirements of a diagnostic radiopharma-
ceutical is the ability to yield a high tumor-to-background
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pharmaceutical also requires high uptake in the tumor for
prolonged time.
Various radionuclides are available for either imaging or
therapeutic applications of peptides (Table 1).
99mTc is
often used in SPECT because of its ideal physical prop-
erties (t1/2 = 6h , Ec = 140 keV) and its good, wide
availability. The t1/2 is long enough to synthesize the
99mTc-labeled radiopharmaceutical and perform imaging,
and at the same time short enough to minimize the radia-
tion dose to the patient (Fichna and Janecka 2003). In
addition,
111In is often used. Due to its half-life of 2.8 days,
111In can be used to perform scans at later time-points post-
injection (p.i.).
123I is used as a tracer in SPECT for
scanning of thyroid.
18F is an important isotope in PET imaging. The
radionuclide is used in 2-ﬂuoro-2-deoxy-D-glucose (FDG),
the most widely used PET tracer. A cyclotron is needed for
the production of
18F and the half-life of the isotope
(110 min) makes rapid and automated chemistry necessary.
In recent years, the use of
68Ga for PET imaging has been
evaluated in several studies (Maecke et al. 2005).
68Ga is
eluted from an in-house
68Ge/
68Ga generator and can be
coupled to a chelator-conjugated biomolecule. Because
of the long half-life of the parent radionuclide
68Ge
(t1/2 = 271 days),
68Ga-based radiopharmaceuticals may
become a very cost-effective alternative for cyclotron-
based tracers.
Peptide receptor-targeted radiotherapy (PRRT) requires
radionuclides with a high cytotoxic potential. Good cyto-
toxic agents are b-particle emitters, with an intermediate
half-life. b-particles with a high energy transfer, such as
90Y, are considered to be appropriate in the treatment of
larger tumors, whereas radionuclides with a lower energy,
such as
177Lu or
131I, are more suitable for treating tumors
with a relatively smaller diameter (O’Donoghue et al.
1995).
To allow radiolabeling with a radiometal, a chelator
conjugated to the peptide is required. Several cyclic and
acyclic bifunctional chelators have been developed, of
which N
a-diethylenetriaminopentaacetic acid (DTPA)
and 1,4,7,10-tetraazacyclododecane-N,N0,N00,N000-tetraacetic
acid (DOTA) and their derivatives are most widely used.
DTPA is useful for
111In labeling, but it is less suitable for
therapeutic purposes, as the
90Y- or
177Lu-DTPA complex
is not stable in vivo over longer time (Fichna and Janecka
2003). DOTA conjugates are especially suitable for
radionuclide therapy, as they can be radiolabeled with
90Y,
177Lu and
111In to yield a stable radiometal–chelator
complex. However, the labeling procedure is more difﬁ-
cult, requiring a heating step that may damage the peptide.
This review will focus on the development and appli-
cation of radiolabeled CCK/gastrin peptides for imaging
and therapy of tumors expressing CCK receptors. We will
discuss preclinical studies as well as clinical (imaging and
therapy) studies with CCK and gastrin peptides.
CCK and CCK receptors
Cholecystokinin (CCK) is a peptide hormone, originally
discovered in the gastrointestinal tract by Ivy and Oldberg
(1928). In 1975, Vanderhaeghen et al. described CCK as a
gastrin-like immunoreactive peptide and indicated that it is
one of the most widespread neuropeptides in the central
nervous system. CCK exerts a variety of physiological
actions in the gastrointestinal tract and in the central
nervous system. CCK was initially characterized as a
33-amino acid sequence, but the peptide showed to be
present in a variety of biologically active molecular forms
such as CCK39, CCK33, CCK8 and CCK4, all derived from
a 115-amino acid precursor molecule. The most abundant
peptide in the brain is CCK8 (Asp-Tyr-Met-Gly-Trp-Met-
Asp-Phe-NH2) (Noble and Roques 1999; Noble et al. 1999).
Receptors for CCK have been pharmacologically clas-
siﬁed based on their afﬁnity for the endogenous peptide
CCK and gastrin. These two ligands share the same ami-
dated C-terminal pentapeptide sequence but differ in sul-
fation of the tyrosine residue at position 6 (gastrin) or 7
(CCK) (Fig. 1) (Wank 1998;B e h re ta l .1999).
Three types of CCK receptors have been identiﬁed so
far. The CCK1 (formerly known as CCK-A) receptor was
ﬁrst characterized in pancreatic acinar cells (Sankaran et al.
1980), and is mainly located in the periphery, but also
in some regions of the brain. In contrast to the high
expression of this receptor in various organs in the gas-
trointestinal tract in rodents, its expression in humans is
limited. The CCK2 (formerly known as CCK-B) receptor
Table 1 Radionuclides for diagnostic and therapeutic application
Nuclide Half-life (h) Energy (keV)
99mTc 6 c 140
111In 67 c 171, 245
Auger e
- 2–30
18F 1.8 b
? 634
c 511
68Ga 1.1 b
? 1,899
c 511
131I 192 bmax
- 606
c 363
90Y6 5 bmax
- 2,964
177Lu 161 bmax
- 498
c 113, 208
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123was discovered in the brain (Innis and Snyder 1980) and is
located in the brain and in the stomach, pancreas and gall
bladder. In the gastrointestinal tract, activation of this
receptor by gastrin stimulates gastric acid secretion (Noble
and Roques 1999). The CCK1 and CCK2 receptors have
been shown to differ by their relative afﬁnity for gastrin
binding, their differential distribution and their molecular
structure. The CCK1 receptor binds sulfated CCK with a
500- to 1,000-fold higher afﬁnity than non-sulfated CCK.
The CCK2 receptor binds gastrin and CCK with almost the
same afﬁnity and does not discriminate between the sul-
fated and non-sulfated CCK analogs (Noble and Roques
1999). Gastrin receptors in the stomach and CCK2 recep-
tors in the brain were initially thought to be distinct CCK
receptors, based on their different relative afﬁnities for
CCK and gastrin-like peptides. However, subsequent
cloning of both receptors revealed their identical molecular
identity (Kopin et al. 1992; Wank 1995). The CCK2
receptor therefore is also referred to as gastrin receptor.
The third type of CCK receptors is the CCK2i4sv
receptor, a splice variant of the CCK2 receptor, ﬁrst iso-
lated and characterized by Hellmich et al. (Hellmich et al.
2000). The CCK2i4sv receptor was discovered in human
colorectal cancer cells and stimulates cell growth through a
gastrin-independent mechanism. This receptor is generated
by intron 4 retention during RNA processing, resulting in a
69-amino acid insert in the third intracellular loop domain
of the receptor (Hellmich et al. 2000).
All CCK receptors belong to the superfamily of
G-protein coupled receptors (GPCRs), which means that
they consist of seven transmembrane domains and activate
a second messenger pathway after internalization upon
binding of a ligand (Be ´he ´ and Behr 2002). Several binding
sites for ligand binding to CCK2 receptor have been
identiﬁed in mutagenesis studies (Fig. 2) (Foucaud et al.
2008). Both the C-terminal phenylalanine of the CCK8
peptide and the tryptophan are located in a hydrophobic/
aromatic pocket with residues from different transmem-
brane helices. The carbonyl group of the amide accepts a
hydrogen bond from the hydroxyl oxygen of Tyr189 and
the nitrogen amide donates a hydrogen bridge to Asn353.
The sulfate of CCK8 binds to the receptor by two hydrogen
bonds with Arg57 and Tyr61 in helix 1.
Tumor expression of CCK receptors
CCK1 and CCK2/gastrin receptors have been identiﬁed in
several normal tissues and in various tumors. The group of
Reubi identiﬁed an unexpected high incidence ([90%) of
CCK2 receptors in medullary thyroid carcinomas (MTC),
whereas differentiated thyroid cancers do not express
CCK2 receptors (Reubi and Waser 1996). Medullary thy-
roid carcinomas comprise 3–12% of all thyroid cancers.
The 10-year survival of MTC patients is approximately
30%, clearly worse than the survival rates of patients with
other forms of differentiated thyroid cancers. One of the
major reasons for this is probably that MTCs do not
accumulate radioiodine, making radioiodine therapy use-
less in MTC patients (Be ´he ´ and Behr 2002).
CCK2 receptors are also frequently found in astrocyto-
mas (65%) and stromal ovarian cancers (100%). Several
other tumor types, such as meningiomas, endometrial and
ovarian adenocarcinomas, breast carcinomas and gastro-
enteropancreatic tumors occasionally express CCK2
receptors. CCK1 receptors are rarely expressed in human
tumors (Reubi et al. 1997).
Although earlier studies reported CCK2 receptors in
colon cancers and gastric cancers (Upp et al. 1989), further
research failed to ﬁnd high-afﬁnity CCK2 receptors in most
Fig. 1 Molecular structure of a
CCK8 and b minigastrin: n = 0,
MG11; n = 5, MG0
Radiolabeled CCK/gastrin peptides for imaging and therapy 1051
123of these tumors (Imdahl et al. 1995). Small cell lung can-
cers often express CCK2 receptors (incidence 89%),
whereas non-small lung cancers do not express these
receptors (incidence\6%) (Matsumori et al. 1995;K o ¨rner
et al. 2009).
The splice variant of the CCK2 receptor, the CCK2i4sv
receptor, is expressed in human colorectal cancers and
pancreatic cancers, but not in normal colorectal mucosa
(Hellmich et al. 2000; Smith et al. 2002). However,
expression levels of the CCK2i4sv receptor may be too low
to allow sufﬁcient targeting with radiolabeled peptides, as a
recent study showed rare CCK2i4sv mRNA expression in
pancreatic, gastric and colorectal carcinomas (Ko ¨rner et al.
2009). This study showed high incidence of both the CCK2
and the CCK2i4sv receptor in insulinomas (both 100%),
gastrointestinal stromal tumors (both 100%) and SCLC
(resp. 89 and 67%).
CCK and gastrin peptides
A lot of research has been done on developing suitable
radioligands for targeting the CCK2 receptor in vivo. A
variety of radiolabeled CCK/gastrin-related peptides has
been synthesized and characterized by different research
groups (Table 2). All peptides have the C-terminal CCK
receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-
NH2 in common or derivatives thereof. The presence of an
intact C-terminal sequence showed to be crucial for
receptor binding, although the methionine may be replaced
by leucine or norleucine (Behr et al. 1998, 1999). CCK
receptor-targeting peptides are discussed in the following
paragraphs. The peptides can be categorized based on the
sequence of their parent peptide (gastrin or CCK) and on
their form, i.e., linear, cyclic, multimers. (Pre)clinical
studies with CCK and gastrin receptor-binding peptides are
reviewed below.
Preclinical studies with linear CCK2R binding ligands
One of the endogenous ligands for the CCK2 receptor is
gastrin, a peptide that has been an important lead com-
pound in the search for new ligands of the receptor. In the
late 1990s, Behr et al. (1998) showed promising results for
the diagnostic and therapeutic application of
131I-radioio-
dinated human gastrin-I. This synthetic heptadecapeptide
has an afﬁnity for CCK2 receptors in the low nanomolar
range, whereas its afﬁnity for CCK1 receptors was at least
four orders of magnitude lower. Gastrin-I has a pyroglu-
tamate moiety at its N-terminus, which is known to protect
peptides from rapid enzymatic degradation. Behr et al.
were able to demonstrate the feasibility of
131I-labeled
gastrin-I to target CCK2 receptor-expressing tumors in a
patient, as well as CCK receptor expression in normal
tissues. Furthermore, Behr and his group investigated a
series of 18 radioiodinated gastrin and CCK derivatives for
targeting CCK receptors in vivo (Behr et al. 1999). Sul-
fated CCK analogs and some non-sulfated gastrin analogs
had the highest afﬁnities (IC50 values in the nanomolar
range), whereas desulfation or the complete removal of the
N-terminally located tyrosine of the peptide led to a loss of
afﬁnity. Replacement of the pentaglutamate sequence by
similarly polar but uncharged pentaglutamine caused a
reduction in afﬁnity and a decreased uptake in CCK2R
expressing tissues (Behr et al. 1999).
Behr and Be ´he ´ investigated two DTPA-conjugated
peptides in this study as well. The ﬁrst amino acid of
minigastrin (MG), leucine, was exchanged for D-Glu. Both
peptides (minigastrin and D-Glu
1-minigastrin) were deriv-
atized with the benzylisothiocyanate derivative of DTPA
for labeling with
111In and
90Y. DTPA-D-Glu
1-minigastrin
showed an improved radiochemical stability over the cor-
responding DTPA-Leu-minigastrin (t1/2 is 2.5 times higher)
and was therefore used in the subsequent studies (Be ´he ´
and Behr 2002;B e ´he ´ et al. 2003). The advantage of
Fig. 2 Serpentine
representation of human
CCK2R (Foucaud et al. 2008).
Amino acids of the binding and/
or activation site are marked and
numbered (reprinted from
Foucaud et al. (2008) with
permission of Elsevier)
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123conjugation of DTPA via an isothiocyanate is that the
resulting peptide conjugate has ﬁve carboxyl functions
available for coordination, whereas DTPA-conjugated
peptides normally have four. The additional carboxyl
moiety may provide better stability for chelating radio-
metals such as
90Y, which is known to form rather unstable
complexes with conventional DTPA-coupled peptides
(Fichna and Janecka 2003; Aloj et al. 2004a).
At the same time that Be ´he ´ and Behr published their
results on gastrin analogs, Reubi et al. (1998) developed a
series of non-sulfated CCK8 analogs. The peptides were
N-terminally coupled to DTPA or DOTA to allow
radiometal binding. A high speciﬁcity towards CCK2
receptors was reported, which was determined by the
presence of non-sulfated tyrosine. Wank (1995) had
already demonstrated that a sulfated tyrosine in position 27
of CCK-33 is essential for CCK and its derivatives to
display afﬁnity for either CCK1 or CCK2 receptors. A
CCK8 analog with a non-sulfated tyrosine results in
selective binding to the CCK2 receptor. Analogs in which
methionine in position 3 and 6 was replaced by norleu-
cine—to prevent oxidation causing a loss of afﬁnity—had
similar binding properties (IC50 1.5 nM) as native CCK8
(IC50 2.3 nM) and showed increased plasma stability.
Table 2 Minigastrin and CCK8 analogs and their afﬁnities for the CCK2 receptor (Reubi et al. 1998; Laverman et al. 2004; Nock et al. 2005;
Mather et al. 2007; Good et al. 2008; Roosenburg et al. 2009; von Guggenberg et al. 2009)
Peptides Peptide sequence Afﬁnity
Minigastrin analogs
Minigastrin Leu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 IC50 = 1n M
a
111In-DTPA-MG0 D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 IC50 = 0.98 nM
b
111In-DOTA-MG11 D-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 IC50 = 4.8 nM
b
111In-DOTA-MG11(Nle) D-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 IC50 = 9.9 nM
b
111In-DOTA-H2-Met His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 Ki = 3.9 nM
c
111In-DOTA-H2-Nle His-His-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 Ki = 11.3 nM
c
111In-DOTA-H6-Met (His)6-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 Ki = 2.1 nM
c
[
99mTc]2N4
0, D-Glu
1-MG (
99mTc-Demogastrin 1) D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 Kd = 1.05 nM
d
[
99mTc]2N4
0-1,Gly
0,D-Glu
1-MG (
99mTc-Demogastrin 2) Gly- D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 Kd = 1.02 nM
d
99mTc-HYNIC-MG11 Kd = 3.97 nM
e
99mTc-HYNIC-cyclo-MG1 -D-Glu D-Lys-Trp-Met-Asp-Phe-NH2
       Ala   Tyr 
Kd = 19.1 nM
e
99mTc-HYNIC-cyclo-MG2 -D-Glu D-Lys-Trp-Nle-Asp-Phe-NH2
      Ala   Tyr 
Kd = 21.2 nM
e
CCK8 analogs
111In-DTPA-CCK8 D-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 IC50 = 2.3 nM
b
111In-DTPA-CCK8(Nle) D-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2 IC50 = 1.5 nM
b
99mTc-HYNIC-CCK8 D-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 IC50 = 10 nM
f
99mTc-HYNIC-sCCK8 D-Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 IC50 = 3n M
f
111In-DOTA-sCCK8[Phe
2(p-CH2SO3H), Nle
3,6] D-Asp-Phe(p-CH2SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 IC50 = 11.6 nM
g
111In-DOTA-sCCK8[Phe
2(p-CH2SO3H), HPG
3,6]* D-Asp-Phe(p-CH2SO3H)-HPG-Gly-Trp-HPG-Asp-Phe-NH2 IC50 = 13.2 nM
g
*HPG = homopropargylglycine
a Determined in cell suspension of TT cells (Behr et al. 1999)
b Determined on surgically extracted human tumours (Reubi et al. 1998; Good et al. 2008)
c Determined on transfected AGS-CCK2R cells (Mather et al. 2007)
d Determined in a saturation assay with AR42J cells membranes (Nock et al. 2005)
e Determined in a saturation assay with AR42J cells (von Guggenberg et al. 2009)
f Determined on transfected CHO-CCK2R cells (Laverman et al. 2004)
g Determined on transfected HEK293-CCK2R cells (Roosenburg et al. 2009)
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123These analogs showed promising results in healthy rats:
rapid clearance by renal excretion, increased plasma sta-
bility and low uptake and retention in the main peripheral
soft tissues. Based on this study, Reubi et al. concluded that
non-sulfated CCK analogs are highly promising for CCK2
receptor scintigraphy.
Subsequently, de Jong et al. (1999) investigated the
potential of
111In-DOTA-CCK8[Nle
3,6] for peptide receptor
radionuclide therapy. This study concerned internalization,
biodistribution and tumor targeting and demonstrated a
receptor-speciﬁc and time- and temperature-dependent
internalization of
111In-DOTA-CCK8 in AR42J cells (rat
pancreatic tumor). Evaluation in a syngeneic rat tumor
model showed good targeting of CA20948 tumors (rat
pancreatic tumor). There was a speciﬁc uptake of
111In-DOTA-CCK8[Nle
3,6] in CCK2 receptor-expressing
tissues and a low uptake in receptor-negative organs. Also,
much higher tumor-to-blood ratios were found for the
111In-
labeled peptide when compared to a
131I-labeled peptide,
showing that residualizing radionuclides such as
111In have
advantages over
131I. After internalization and subsequent
metabolism of the radiolabeled ligand in the lysozomes,
111In is retained in the cell, resulting in a prolonged resi-
dence time in the tumor cells. In contrast,
131I is released
from the cell after internalization.
We studied two
99mTc-labeled CCK8 analogs for scin-
tigraphic imaging of CCK receptors, non-sulfated CCK8
(nsCCK8) and sulfated CCK8 (sCCK8) (Laverman et al.
2004). We demonstrated that uptake of the sulfated analog,
99mTc-HYNIC-sCCK8, in both CCK1 and CCK2 receptor-
expressing tumors in mice was approximately 15-fold
higher than that of the non-sulfated analog. More recently,
we showed that
111In-labeled sCCK8 and minigastrin also
has afﬁnity for the splice variant of the CCK2 receptor, the
CCK2i4sv receptor (Laverman et al. 2007). Tumor uptake
of
111In-labeled sCCK8 in CCK2i4sv receptor-positive
tumors was similar to the uptake in CCK2 receptor-
expressing tumors.
In 2004, Aloj et al. published results obtained with
111In-
DTPA-Glu-Gly-CCK8, using DTPA as a chelator (Aloj
et al. 2004a, b). They used the same chelator that Behr and
Be ´he ´ used in their earlier studies with minigastrin (Be ´he ´
et al. 2003). A glycine residue was introduced as a spacer
between the chelator and the peptide. The peptide conju-
gates showed good afﬁnity for the CCK2 receptor. In line
with the results of Be ´he ´, chelation of
111In was found to be
more stable (6% transchelation rate at 24 h in fetal bovine
serum), resulting in low background accumulation and
fast blood clearance. Tumor uptake of
111In-DTPAGlu-G-
CCK8 in A431-CCK2R xenografts was 4% ID/g at 30 min
p.i. Renal retention was 5.5% ID/g (Aloj et al. 2004a).
Three
99mTc-labeled minigastrin analogs were investi-
gated by Nock et al. (2005) for targeting the CCK2/gastrin
receptor. They derivatized minigastrin with an open-chain
tetraamine either directly (Demogastrin 1) or via different
spacers (Demogastrin 2 and 3), to achieve stable labeling
with
99mTc. After injection in mice, tumor-to-nontarget
ratios were especially favorable for
99mTc-Demogastrin 2
(with a glycine between the chelator and the peptide). The
high kidney uptake could be reduced by coinjection of
poly-Glu-containing peptides. Similar observations were
reported by Be ´he ´ et al. (2005) after intraperitoneal injec-
tion of (Glu)x peptides in rats. Scintigraphy in one MTC
patient revealed all known lesions at 90 min after injection,
providing high quality images after 4 h.
Mather et al. (2007) aimed to identify a radioligand that
combined the relatively high tumor uptake of peptides
belonging to the gastrin family with the low renal uptake
seen with CCK derivatives. They prepared a library of
peptide-DOTA and peptide-DTPA conjugates based on the
C-terminal structure of minigastrin. Removal of the pen-
taglutamate sequence present in minigastrin resulted in a
strong reduction in kidney uptake from 60 to 3% ID/g, but
also reduced tumor uptake by a factor of 3. Replacement of
the pentaglutamate sequence in minigastrin with a hexa-
histidine tag resulted in a similar reduction in kidney and
tumor uptake. They found that a dihistidine analog (DOTA-
His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) showed
the best results in terms of tumor-to-kidney ratios, with a Ki
value of 3.9 nM. Radiolabeling of these analogs, however,
needed heating up to 100C (instead of 70C), resulting in a
high level of oxidation of the methionine residues. The most
effective, clinically acceptable antioxidant to overcome this
problem was monothioglycerol (MTG). Both the in vitro
receptor afﬁnity and the in vivo tumor uptake were reduced
by substitution of the methionine residue with nonoxidiz-
able norleucine. These data are in contrast with that as
reported by Reubi et al. in their study on CCK8 analogs
(Reubi et al. 1998) and with what we found (Roosenburg
et al. 2009). In the search for stabilized sCCK8 analogs we
synthesized peptides in which the methionine residues were
replaced by either norleucine or homopropargylglycine to
prevent oxidation. Furthermore, the sulfated tyrosine was
replaced by a stable synthetic isostere, phenylalanine sul-
fonate. In vitro studies showed that the peptides were
resistant to oxidation, whereas the afﬁnity was retained in
the low nanomolar range. Biodistribution studies in AR42J-
tumor-bearing mice showed a tumor uptake of
111In-
DOTA-sCCK8[Phe
2(p-CH2SO3H), Nle
3,6] comparable to
111In-DOTA-sCCK8. Imaging was performed with
111In-
DOTA-sCCK8[Phe
2(p-CH2SO3H), HPG
3,6] (Fig. 3). These
compounds are currently being further investigated for its
potential in PRRT.
In mice, Good et al. (2008) reported a decreased circula-
tory half-life and lower tumoruptake of
111In-DOTA-MG11
(D-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)incomparison
1054 S. Roosenburg et al.
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111In-DTPA-MG0 (D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-
Met-Asp-Phe-NH2). Although tumor-to-kidneys ratios were
higher for
111In-DOTA-MG11, the absolute tumor uptake in
AR42J tumors was lower.Be ´he ´ etal. (2005) showed that the
high renal uptake of
111In-DTPA-MG0 in mice could be
signiﬁcantly reduced by coinjection of polyglutamic acids,
whereas tumor uptake was not impaired. Therefore, the
diagnostic efﬁcacy of this compound may be better than that
of
111In-DOTA-MG11.
Preclinical studies with cyclic peptides
De Luca et al. (2006) designed a library of 14 cyclic CCK8
analogs, based on the structural details of the complex
between CCK8 and the CCK2 receptor fragment. They
identiﬁed structural requirements for preferential binding
to the CCK2 receptor. The results of the binding assays
with this series of 14 peptides conﬁrmed that the tetra-
peptide Trp30-Met31-Asp32-Phe33 is signiﬁcant to bind-
ing, as was already stated earlier by Be ´he ´ and Behr (Behr
et al. 1998, 1999). De Luca et al. found that, in fact, the
most active molecules maintain the turn region centered
around Trp30-Met31 and that the Phe33 side chain must be
conserved. Nevertheless, the IC50 values of all the tested
cyclic analogs were much higher (1,000-fold or more) than
that of CCK8 itself.
Linear gastrin analogs exist under various folded con-
formations in solution. As cyclization showed to improve
the in vivo characteristics of other peptides such as RGD
analogs (Dijkgraaf et al. 2006; Haubner 2006), Von Gug-
genberg et al. (2009) designed and evaluated two cyclic
minigastrin analogs (cyclo-MG), based on MG11. They
synthesized two MG analogs containing unnatural amino
acids in the peptide chain and a cyclic constraint that was
introduced through an internal amide bond (Table 2). In
position 1, D-Glu was incorporated in the peptide through
the c carboxylic group. In position 9, Gly was replaced by
D-Lys. These modiﬁcations allowed cyclization by lacta-
mization between the side-chain amino group of D-Lys
9
and the a-carboxylic group of D-Glu
1. To avoid oxidation
during the radiolabeling process, Met was replaced by Nle
in position 11. The peptide was derivatized with HYNIC on
the N-terminus to allow radiolabeling with
99mTc. In vitro
studies showed that receptor binding was impaired by
cyclization, possibly related to the reduced ﬂexibility of the
peptide backbone. However, internalization in AR42J cells
of both cyclic MG analogs was similar to that of linear
HYNIC-MG11. Tumor uptake of[3% ID/g at 1 h p.i. was
observed in nude mice with s.c. AR42J tumors for both
analogs, whereas the linear MG1 (
99mTc-HYNIC-c-D-Glu-
Ala-Tyr-D-Lys-Trp-Met-Asp-Phe-NH2) analog showed a
very low tumor uptake of \0.3% ID/g. The overall bio-
distribution of
99mTc-HYNIC-cyclo-MG1 was similar to
that of
99mTc-HYNIC-MG11. It was claimed that cycliza-
tion is important to maximize tumor uptake of this peptide,
but the overall pharmacokinetic proﬁle was not improved.
Stabilization of the peptide requires further optimization to
obtain a radioligand suitable for diagnostic and/or thera-
peutic applications. Stabilization could possibly also be
achieved by dimerization of MG11, which was shown to be
effective in increasing tumor uptake while maintaining low
kidney retention (Sosabowski et al. 2008).
Clinical studies with CCK and gastrin analogs
Several studies in MTC patients have been performed with
both gastrin-like (Behr et al. 1999;B e ´he ´ and Behr 2002;
Nock et al. 2005; Gotthardt et al. 2006; Fro ¨berg et al. 2009)
and CCK-like (Kwekkeboom et al. 2000) peptides in the
past few years. A direct comparison of the results of these
studies is difﬁcult, as different protocols were used.
The evaluation of the CCK8 analog
111In-DTPA-
CCK8[Nle
3,6] in patients was reported by Kwekkeboom
et al. (2000). The results showed high background activity
levels in the scintigraphic images, relatively low uptake
in the strongly CCK receptor-positive stomach and a
rapid degradation of
111In-DTPA-CCK8[Nle
3,6] in serum.
Fig. 3 Representative animal SPECT/CT image showing biodistri-
bution of
111In-DOTA-sCCK8[Phe
2(p-CH2SO3H), HPG
3,6]a t1 h
after administration. Radiotracer uptake is clearly visible in the
CCK2R-transfected A431 tumor (left shoulder, arrow) and kidneys,
whereas no uptake is noted in the mock-transfected A431 tumor (right
ﬂank, arrow head)
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two patients, small MTC lesions could not be detected.
Behr et al. (1999) reported a pilot clinical study with
111In-DTPA-MG0 in four MTC patients. They found
CCK2 receptor-targeting in physiologically CCK2 recep-
tor-expressing tissues (e.g. the stomach) as well as in
metastatic MTC lesions. In 2002, Behr and Be ´he ´ published
a clinical study with
111In-DTPA-MG0 for both imaging
and therapy in 75 and 8 MTC patients, respectively (Be ´he ´
and Behr 2002). In the imaging study, 185–259 MBq of
111In-DTPA-MG0 was injected and whole body scans were
performed at several time-points after injection. They
found that normal organ uptake was restricted to the
stomach, caused by high physiological CCK2 receptor
expression, and to the kidneys, due to tubular reabsorption.
In patients known to have the disease, all of the tumors that
were found with conventional imaging modalities were
already visualized at 1 h p.i., although optimal scans were
obtained at 24 h p.i. More importantly, in 29 out of 32
MTC patients with occult disease, at least one lesion was
visualized. Uptake in the liver and spleen was very low.
Eight patients with advanced and rapidly progressing
metastatic MTC were injected with high activity doses of
90Y-labeled DTPA-MG0. The study was designed starting
at 1.11 GBq/m
2 per injection with a maximum of four
injections. Every fourth patient the dose was escalated by
1.11 GBq/m
2. Three patients treated with the lowest
activity dose did not show any signs of toxicity. All three
patients treated at 1.48 GBq/m
2 developed transient and
usually mild (Bgrade 3) hematologic toxicity. One of the
two patients at 1.85 GBq/m
2 developed transient grade 4
thrombocytopenia and grade 1 nephrotoxicity. Four
patients experienced stabilization of their previously rap-
idly progressing disease, lasting for up to 36 months.
However, two patients developed severe renal failure 1–2
years after radiopeptide therapy. In summary, the thera-
peutic effects of
90Y-DTPA-MG0 were encouraging, but
renal toxicity in a few patients was rather severe. Therefore
the authors aimed to continue the studies with Auger
electron-emitting radionuclides such as
111In instead of b
?-
emitting
90Y, as these showed much less nephrotoxicity in
preclinical settings.
Gotthardt et al. (2006) reported a tumor detection rate of
87% by means of scintigraphy using
111In-DTPA-MG0 in a
group of 26 MTC patients. Most of the patients in that
study, however, had known metastases and tumor lesions
were found in only one patient in the group of patients with
occult disease.
Recently, Fro ¨berg et al. (2009) investigated and com-
pared
99mTc-Demogastrin 2, evaluated earlier in vitro and
in vivo by Nock et al. (2005), with
111In-DOTA-CCK8 and
111In-DOTA-MG11.An earlier study of this group (Bre-
eman et al. 2008) involved optimizing the radiolabeling
conditions and investigating the preclinical aspects of the
compounds.
99mTc-Demogastrin 2 showed the best visu-
alization, which may be due to better imaging properties of
99mTc compared to
111In. Figure 4 shows examples of the
comparative images of the three radiopharmaceuticals
studied.
99mTc-Demogastrin 2 visualized all known lesions
in six MTC patients, whereas several known lesions were
missed with the other two compounds. In addition, in four
patients, new lesions in neck, brain, bone and liver were
discovered with
99mTc-Demogastrin 2. Both
111In-DOTA-
CCK8 and
111In-DOTA-MG11 showed to be less suitable
for scintigraphy, as the sensitivity as well as the uptake in
visible lesions was limited and appeared to be insufﬁcient
for radionuclide therapy in these tumors. Moreover, the
stability of
111In-DOTA-MG11 was low. Although this
peptide was reported to be stable in ex vivo human serum,
an HPLC analysis of blood samples from patients in this
study showed that only 10% of the original peptide was
still intact 10 min after administration.
99mTc-Demogastrin
2 was more stable, illustrated by the fact that more than
60% of the radioligand was still intact at the same time
point. Visual evaluation showed that renal uptake of
99mTc-
Demogastrin 2 was in the same range as the uptake of
Fig. 4 Scintigrams of a patient (anterior and posterior views): ﬁrst
row
99mTc-Demogastrin 2 at 4 and 24 h, second row
111In-DOTA-
MG11 at 4 and 24 h and thirrd row
111In-DOTA-CCK at 4 and 24 h.
Tumor lesions (and stomach) are best visible on
99mTc-Demogastrin 2
scintigraphy; some lesions are marked with arrows [reprinted with
kind permission of Springer Science ? Business Media from Fro ¨berg
et al. (2009)]
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111In-DOTA-CCK8. Therefore,
99mTc-Demogastrin 2 appeared to be a promising diag-
nostic tool in patients with MTC.
Conclusion
We have discussed a range of gastrin and CCK analogs for
targeting CCK2R positive tumors in this review. As is the
case for all peptides used in peptide receptor radionuclide
imaging and therapy, CCK/gastrin receptor-targeting pep-
tides should meet some basic criteria, such as low nano-
molar receptor afﬁnity, rapid and efﬁcient accumulation in
the tumor, low uptake and rapid wash-out in/from normal
tissues and good in vivo stability.
Of the peptides discussed in this paper, the minigastrin
analog MG0 showed good tumor targeting, but this analog
has the disadvantage of extremely high renal retention. The
N-terminally truncated analog MG11 displayed a similar
receptor afﬁnity, with a much lower kidney accumulation.
However, due to poor in vivo stability, the accretion of this
peptide in the tumor is much lower. In an attempt to
improve stability, a cyclic variant of this MG11 was syn-
thesized. However, this did not improve the stability. In
another approach, the dimerization of MG11 does lead to
improved tumor-background ratios, while maintaining low
kidney uptake. Further studies will be required to investi-
gate the stability of this dimeric minigastrin analog.
Finally, incorporation of synthetic amino acids may result
in improved in vivo stability.
So far (unsulfated) CCK8 analogs combine good tumor
targeting with low kidney retention, making these peptide
suitable candidates for PRRT. Future studies are warranted
to establish the optimal CCK2R targeting peptide.
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